<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00072358</url>
  </required_header>
  <id_info>
    <org_study_id>03-077</org_study_id>
    <secondary_id>MSKCC-03077</secondary_id>
    <nct_id>NCT00072358</nct_id>
  </id_info>
  <brief_title>Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With Neuroblastoma</brief_title>
  <official_title>Phase II Study of Anti-GD2 3F8 Antibody and GM-CSF for High-Risk Neuroblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies, such as monoclonal antibody 3F8, can locate tumor cells and
      either kill them or deliver tumor-killing substances to them without harming normal cells.
      Colony-stimulating factors, such as sargramostim, may increase the number of immune cells
      found in bone marrow or peripheral blood. Combining monoclonal antibody 3F8 with sargramostim
      may cause a stronger immune response and kill more tumor cells.

      PURPOSE: Phase II trial to study the effectiveness of combining monoclonal antibody 3F8 with
      sargramostim in treating patients who have neuroblastoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the efficacy of sargramostim (GM-CSF) in enhancing monoclonal antibody
           3F8-mediated ablation in patients with high-risk neuroblastoma.

        -  Determine the prognostic impact of minimal residual bone marrow disease on relapse-free
           survival of patients treated with this regimen.

        -  Compare the effects of short-term (2-hour intravenous) vs prolonged (subcutaneous
           release) daily GM-CSF on granulocyte activation, in order to establish the optimal route
           for tumor-cell kill in these patients.

      OUTLINE: This is an open-label study. Patients are stratified according to evaluable disease
      (yes [primary refractory bone marrow disease] vs no [no evidence of disease]).

      Patients receive sargramostim (GM-CSF) subcutaneously on days -5 to 4 and monoclonal antibody
      3F8 IV over 0.5-1.5 hours on days 0-4. Treatment repeats every 3 weeks for 4 courses and then
      every 8 weeks for up to a total of 24 months in the absence of disease progression or
      unacceptable toxicity.

      Beginning after 2 courses of GM-CSF and monoclonal antibody 3F8, patients also receive oral
      isotretinoin twice daily on days 1-14 (when no monoclonal antibody 3F8 is administered).
      Treatment with isotretinoin repeats approximately every 28 days for 6 courses.

      PROJECTED ACCRUAL: A total of 340 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2003</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy at completion of treatment</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Relapse-free survival every 3 months</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare granulocyte activation in patients treated with short-term vs prolonged daily exposure to sargramostim (GM-CSF) after 4 courses</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Simplify treatment with consequent reduction in cost</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">340</enrollment>
  <condition>Neuroblastoma</condition>
  <arm_group>
    <arm_group_label>patients have refractory bone marrow disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This phase II trial of the anti-GD2 murine IgG3 monoclonal antibody 3F8 combined with granulocyte-macrophage colony stimulating factor (GM-CSF) will assess response of minimal residual disease (MRD) in patients with high-risk neuroblastoma (NB) and help establish the optimal way to use GM-CSF.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>patients have no evidence of disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This phase II trial of the anti-GD2 murine IgG3 monoclonal antibody 3F8 combined with granulocyte-macrophage colony stimulating factor (GM-CSF) will assess response of minimal residual disease (MRD) in patients with high-risk neuroblastoma (NB) and help establish the optimal way to use GM-CSF.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti-GD2 murine IgG3 monoclonal antibody 3F8</intervention_name>
    <description>The total dosage of 3F8 per cycle is the same as in prior trials (100 mg/m2), administered at 20 mg/m2/day and infused over ~1.5 hr or less (0.5 hr is customary), with analgesics and antihistamines used as needed for expected side-effects. 3F8 is started ~1 hr after completion of GM-CSF administration. GM-CSF is dosed at 250 mcg/m2/day from day -5 to day +1 (Wednesday to Tuesday is customary) , and is 500 mcg/m2/day thereafter (i.e., on days +2 to +4; Wednesday to Friday), as in the predecessor protocol.18,74 Patients come off study if progressive disease occurs or if there is life-threatening grade 4 toxicity from 3F8; otherwise, patients will receive a minimum of 4 cycles of treatment and will continue treatment through 24 months. It is expected that patients will receive ~10 cycles.</description>
    <arm_group_label>patients have refractory bone marrow disease</arm_group_label>
    <other_name>patients (enrolled on study for treatment of primary refractory disease), the</other_name>
    <other_name>break between end of a cycle of 3F8/GM-CSF and start of next cycle is 2-to-4-weeks through 4</other_name>
    <other_name>cycles after achievement of CR in BM; subsequent breaks are ~8 weeks. In this</other_name>
    <other_name>group, isotretinoin is started after documentation of response to, and after</other_name>
    <other_name>&gt;2 cycles of, 3F8/GM-CSF.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti-GD2 murine IgG3 monoclonal antibody 3F8</intervention_name>
    <description>The total dosage of 3F8 per cycle is the same as in prior trials (100 mg/m2), administered at 20 mg/m2/day and infused over ~1.5 hr or less (0.5 hr is customary), with analgesics and antihistamines used as needed for expected side-effects. 3F8 is started ~1 hr after completion of GM-CSF administration. GM-CSF is dosed at 250 mcg/m2/day from day -5 to day +1 (Wednesday to Tuesday is customary) , and is 500 mcg/m2/day thereafter (i.e., on days +2 to +4; Wednesday to Friday), as in the predecessor protocol.18,74 Patients come off study if progressive disease occurs or if there is life-threatening grade 4 toxicity from 3F8; otherwise, patients will receive a minimum of 4 cycles of treatment and will continue treatment through 24 months. It is expected that patients will receive ~10 cycles.</description>
    <arm_group_label>patients have no evidence of disease</arm_group_label>
    <other_name>For Group 2 patients (enrolled on study in CR/VGPR, i.e., with no evidence of disease),</other_name>
    <other_name>the break between end of a cycle and start of next cycle is 2-to-4 weeks through 4 cycles;</other_name>
    <other_name>subsequent breaks are ~8 weeks. Isotretinoin is started after cycle 2 of 3F8/GM-CSF. Road</other_name>
    <other_name>map/schema is in section 4.2. Regarding patients in second or greater CR from relapse in the</other_name>
    <other_name>central nervous system, if they develop early HAMA which precludes timely completion of the</other_name>
    <other_name>minimum of 4 cycles of 3F8/GM-CSF, they are eligible to go off protocol, to be treated with</other_name>
    <other_name>low-dose maintenance regimens of irinotecan,94 temozolomide,95 or the two agents combined;96</other_name>
    <other_name>they can resume treatment with 3F8/GM-CSF if HAMA becomes negative.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of neuroblastoma by histopathology OR bone marrow metastases and high urine
             catecholamine levels

          -  Disease must meet risk-related treatment guidelines and any of the following
             International Neuroblastoma Staging System stages:

               -  Stage 4 with (any age) OR without (&gt; 18 months of age of age) MYCN amplification

               -  MYCN-amplified other than stage 1

          -  No evidence of disease (i.e., in complete response/remission or very good partial
             response/remission) OR disease resistant to standard therapy (i.e., incomplete
             response in bone marrow)

          -  No progressive disease or MIBG-avid soft tissue tumor

        PATIENT CHARACTERISTICS:

          -  No existing renal, cardiac, hepatic, neurologic, pulmonary, or gastrointestinal
             toxicity â‰¥ grade 3

          -  No human anti-mouse antibody (HAMA) titer greater than 1,000 Elisa units/mL

          -  No history of allergy to mouse proteins

          -  No active life-threatening infection

          -  Not pregnant

          -  Negative pregnancy test

        PRIOR CONCURRENT THERAPY:

          -  Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian H. Kushner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 4, 2003</study_first_submitted>
  <study_first_submitted_qc>November 5, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2003</study_first_posted>
  <last_update_submitted>October 3, 2017</last_update_submitted>
  <last_update_submitted_qc>October 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>disseminated neuroblastoma</keyword>
  <keyword>localized unresectable neuroblastoma</keyword>
  <keyword>recurrent neuroblastoma</keyword>
  <keyword>regional neuroblastoma</keyword>
  <keyword>stage 4S neuroblastoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Immunoglobulin G</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Isotretinoin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

